Home
»
Market Trend Reports
»
Monoclonal Antibody Drugs and Indication

Monoclonal Antibody Drugs and Indication

Published: Jun, 2023
Report ID: GVR-MT-100122
Format: PDF, Horizon Databook

No. of Pages/Datapoints: 0
Report Coverage: 2024 - 2030

Overview

The field of Monoclonal Antibodies (MAbs) is experiencing rapid growth in the pharmaceutical industry, making it one of the most dynamic areas of new drug development. Over the next decade, we can expect a significant increase in the utilization and adoption of monoclonal antibody products. In recent years, several blockbuster products such as Rituxan, Remicade, Avastin, Humira, and Herceptin, have received approval and achieved blockbuster status. Furthermore, there are currently over 300 new drugs in clinical trials, indicating the ongoing innovation in this field. Both established biotechnology companies and emerging start-ups are actively involved in the development of monoclonal antibodies. This collaborative effort will contribute to the growing prominence of monoclonal antibody products in the coming years.

MAbs are extremely selective for cancer cells because they attach to proteins on their surfaces & stimulate an immune reaction. Cancer mAbs may hold a significant position within the global mAbs market due to the growing global prevalence of cancer. Moreover, major pharmaceutical companies worldwide are making substantial investments in research and development related to cancer biologics, particularly MAbs. This is because MAbs offer efficiency and reduced toxicity compared to chemotherapy and other treatment modalities for various types of cancer, making them valuable in both the diagnosis and treatment of various cancer types.

Human mAbs are preferred due to lower immunogenicity as compared to other mAb types such as murine, chimeric, and others. The first fully human mAb, Humira, was approved in 2002 with the help of phage display technology and the number of approved fully human mAbs has continued to rise ever since. A majority of the fully human mAbs are produced using transgenic mice, while some are produced by using phage display technology. Rising adoption of transgenic mice is favored by their ability to produce highly specific and affinity-matured antibodies, whereas demand for phage display technologies is supported by scalability, parallelization, and miniaturization attributes offered by the technique. Furthermore, fully human mAbs represent a promising option for treatment of severe, nonmalignant conditions, such as asthma, hypercholesterolemia, atopic dermatitis, and osteoporosis, which can significantly boost market growth. For instance, in December 2022, Aptar Pharma stated that its VP7 nasal multi-dose system will be used to deliver Hibiocy's Vaill Covitrap anti-CoV decongestant spray, which has been recently licensed by Thailand's Food & Drug Administration (FDA).

Topics Covered Under This Study

Attribute	Details
List of top Monoclonal Antibodies	Generic Name Company Source type Route of Administration Indication
Financial Performance	Product wise Revenue
Heat Map Analysis, By Region	North America Europe Asia Pacific Latin America Middle East & Africa

Top Monoclonal Antibodies, 2022

Table 1 List of top monoclonal Antibodies

Sr. No.	Product	Generic Name	Company	Source Type	Route of Administration	Indication
1	Humira	Adalimumab	AbbVie	Human	Subcutaneous	Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis
2	Skyrizi	Risankizumab	AbbVie, Boehringer Ingelheim	Humanized	Subcutaneous	Plaque psoriasis, Crohn's disease
3	Herceptin	Trastuzumab	Roche	Humanized	Intravenous, subcutaneous	Breast cancer, Gastric cancer
4	Avastin	Bevacizumab	Roche	Humanized	Intravenous	Non-small cell lung cancer, Breast ERB2 negative cancer, Renal cell carcinoma, Giloblastoma
5	Mab Thera/Rituxan	Rituximab	Roche	Chimeric	Intravenous	Non-Hodgkin’s Lymphoma, B-cell acute leukemia, Chronic Lymphocytic Leukemia (CLL), Rheumatoid arthritis (RA), Granulomatosis with Polyangiitis (GPA), Pemphigus Vulgaris (PV)
6	Perjeta	Pertuzumab	Roche	Humanized	Intravenous	Breast cancer
7	Ocrevus	Ocrelizumab	Roche	Humanized	Intravenous	Multiple sclerosis
8	Tecentriq	Atezolizumab	Roche	Humanized	Intravenous	Urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, small cell lung cancer, hepatocellular carcinoma, and alveolar soft part sarcoma.
9	Hemlibra	Emicizumab	Roche	Humanized	Subcutaneous	Haemophilia A
10	Gazyvaro	Obinutuzumab	Roche	Humanized	Intravenous	Chronic lymphocytic leukemia (CLL)
11	Xolair	Omalizumab	Roche	Humanized	Subcutaneous	Nasal polyps, allergic asthma & chronic spontaneous urticaria (CSU)
12	Lucentis	Ranibizumab	Roche	Humanized	Intravitreal	Age-related macular degeneration (AMD), diabetic eye disease
13	Actemra	Tocilizumab	Roche	Humanized	Intravenous	Rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (PJIA), systemic juvenile idiopathic arthritis (SJIA), systemic sclerosis-associated interstitial lung disease (SSc-ILD)
14	Keytruda	Pembrolizumab	Merck & Co.	Human	Intravenous	Melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer
15	Simponi	Golimumab	Merck & Co.	Human	Subcutaneous	Rheumatoid arthritis (RA), psoriatic arthritis, Active ankylosing spondylitis (AS), ulcerative colitis (UC),
16	Remicade	Infliximab	Merck & Co.	Chimeric	Intravenous	Rheumatoid arthritis, Ankylosing spondylitis, Ulcerative colitis, Psoriatic arthritis, Psoriasis
17	Remicade	Infliximab	Janssen Pharmaceuticals	Chimeric	Intravenous	Rheumatoid arthritis, Ankylosing spondylitis, Ulcerative colitis, Psoriatic arthritis, Psoriasis
18	Stelara	Ustekinumab	Janssen Pharmaceuticals	Human	Intravenous	Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
19	Tremfya	Guselkumab	Janssen Pharmaceuticals	Human	Subcutaneous	Plaque psoriasis
20	Simponi	Golimumab	Janssen Pharmaceuticals	Human	Subcutaneous	Rheumatoid arthritis (RA), psoriatic arthritis, Active ankylosing spondylitis (AS), ulcerative colitis (UC),
21	Darzalex	Daratumumab	Janssen Pharmaceuticals	Human	Intravenous	Multiple myeloma, light chain (AL) amyloidosis
22	Opdivo	Nivolumab	Bristol-Meyers Squibb	Human	Intravenous	Esophageal cancer, gastroesophageal junction cancer, stomach cancer, colorectal cancer, non-small cell lung cancer, renal cell carcinoma (a type of kidney cancer), melanoma, hepatocellular carcinoma
23	Prolia	Denosumab	Amgen, Inc.	Human	Subcutaneous	Osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone
24	XGEVA	Denosumab	Amgen, Inc.	Human	Subcutaneous	Osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone
25	Repatha	Evolocumab	Amgen, Inc.	Human	Subcutaneous	Hyperlipidemia
26	Vectibix	Panitumumab	Amgen, Inc.	Human	Intravenous	Epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal carcinoma (mCRC)
27	MVASI	Bevacizumab-awwb	Amgen, Inc.	Humanized	Intravenous	Metastatic colorectal cancer
28	KANJINTI	Trastuzumab-anns	Amgen, Inc.	Humanized	Intravenous	Early breast cancer
29	Aimovig	Erenumab	Amgen, Inc.	Human	Subcutaneous	Migraine
30	EVENITY	Romosozumab-aqqg	Amgen, Inc.	Humanized	Subcutaneous	Osteoporosis in women after menopause who are at high risk for fracture
31	Amgevita	Adalimumab	Amgen, Inc.	Human	Subcutaneous	Hidradenitis suppurativa (acne inversa), plaque psoriasis, psoriatic arthritis
32	Dupixent	Dupilumab	Regeneron	Human	Subcutaneous	Atopic Dermatitis, asthma, nasal polyps, eosinophilic esophagitis, and prurigo nodularis.
33	Libtayo	Cemiplimab	Regeneron	Human	Intravenous	Metastatic basal cell carcinoma, cutaneous squamous cell carcinoma (CSCC)
34	Kevzara	Sarilumab	Regeneron	Human	Subcutaneous	Active rheumatoid arthritis (RA)
35	Praluent	Alirocumab	Regeneron	Human	Subcutaneous	Cardiovascular disease to reduce the risk of heart attack, stroke, and certain types of chest pain conditions (unstable angina)

Monoclonal Antibody Drugs, Route Of Administration (%)

Monoclonal Antibody Drugs, Source type (%)

Top Monoclonal Antibodies: Financial Performance, 2018-2022 (USD Million)

Table 2 List of top monoclonal Antibodies

Sr. No.	Product	Company	Revenue (USD Million)
Sr. No.	Product	Company	2018	2019	2020	2021	2022
1	Humira	AbbVie	19,900	19,200	19,800	21,000	21,237
2	Skyrizi	AbbVie, Boehringer Ingelheim	-	350	1,590	2,900	5,100
3	Herceptin	Roche	7,100	6,230	4,120	2,900	2,379
4	Avastin	Roche	6,950	7,310	5,570	3,400	2,356
5	Mab Thera/Rituxan	Roche	6,860	6,690	4,680	2,700	2,304
6	Perjeta	Roche	2,820	3,620	4,850	4,400	4,538
7	Ocrevus	Roche	2,390	3,830	6,110	5,500	6,703
8	Tecentriq	Roche	780	1,960	4,150	3,700	4,128
9	Hemlibra	Roche	220	1,450	3,670	3,300	4,245
10	Gazyvaro	Roche	400	570	700	800	900
11	Xolair	Roche	1,940	2,030	2,120	2,200	2,452
12	Lucentis	Roche	1,680	1,880	1,560	1,500	1,440
13	Actemra	Roche	2,200	2,380	3,230	4,200	2,999
14	Keytruda	Merck & Co.	7,200	11,100	14,400	17,400	20,937
15	Simponi	Merck & Co.	890	830	830	800	706
16	Remicade	Merck & Co.	580	410	330	300	207
17	Remicade	Janssen Pharmaceuticals	5,300	4,400	3,500	3,200	2,343
18	Stelara	Janssen Pharmaceuticals	5,200	6,400	7,700	9,300	9,723
19	Tremfya	Janssen Pharmaceuticals	500	1,000	1,300	2,000	2,668
20	Simponi	Janssen Pharmaceuticals	2,100	2,200	2,200	2,300	2,184
21	Darzalex	Janssen Pharmaceuticals	2,000	3,000	4,190	6,100	7,977
22	Opdivo	Bristol-Meyers Squibb	6,730	7,200	6,990	6,800	8,249
23	Prolia	Amgen, Inc.	2,300	2,700	2,800	3,200	3,628
24	XGEVA	Amgen, Inc.	1,800	1,900	1,900	2,000	2,014
25	Repatha	Amgen, Inc.	600	700	900	1,100	1,296
26	Vectibix	Amgen, Inc.	700	700	800	800	893
27	MVASI	Amgen, Inc.	-	100	800	1,100	900
28	KANJINTI	Amgen, Inc.	-	200	600	500	310
29	Aimovig	Amgen, Inc.	100	300	400	300	410
30	EVENITY	Amgen, Inc.	-	200	400	600	787
31	Amgevita	Amgen, Inc.	-	200	300	400	460
32	Dupixent	Regeneron	920	2,310	4,040	6,300	8,681
33	Libtayo	Regeneron	10	190	340	500	578
34	Kevzara	Regeneron	100	200	260	300	358
35	Praluent	Regeneron	300	280	350	400	467

Request a Free Sample

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

Monoclonal Antibody Drugs and Indication

Overview

Topics Covered Under This Study

Top Monoclonal Antibodies, 2022

Top Monoclonal Antibodies: Financial Performance, 2018-2022 (USD Million)

We are committed towards customer satisfaction, and quality service.

Client Testimonials

ISO Certified

Privacy & Security Compliance

Payment & Banking Partners